Abstract:Background:: In the last years, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused more than 760 million infections and 6.9 million deaths. Currently, remains a public health problem with limited pharmacological treatments. Among the virus drug targets, the SARS-CoV-2 spike protein attracts the development of new anti-SARS-CoV-2 agents. background: In the last years, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused more than 760 million infections and 6.9 million of deaths. Currently, remains as a public health problem with limited pharmacological treatments. Among the virus drug targets, the SARS-CoV-2 spike protein follow be attractive for the development of new anti-SARS-CoV-2 agents. Objective:: The aim of this work was to identify new compounds derived from natural products (BIOFACQUIM and Selleckchem databases) as potential inhibitors of the spike receptor binding domain (RBD)-ACE2h binding complex. objective: The aim of this work was to identify new compounds derived from natural products (BIOFACQUIM and Selleckchem databases) as potential inhibitors of spike receptor binding domain (RBD)-ACE2h binding complex. Methods:: Molecular docking, molecular dynamics simulations, and ADME-Tox analysis were performed to screen and select the potential inhibitors. ELISA-based enzyme assay was done to confirm our predictive model. method: Molecular docking, molecular dynamics simulations, and ADME-Tox analysis were performed to screen and select the potential inhibitors. ELISA-based enzyme assay was done to confirm our predictive model. Results:: Twenty compounds were identified as potential binders of RBD of the spike protein. In vitro assay showed compound B-8 caused 48% inhibition at 50 μM, and their binding pattern exhibited interactions via hydrogen bonds with the key amino acid residues present on the RBD. result: Twenty compounds were identified as potential binders of RBD of the spike protein. In vitro assay showed compound B-8 cause 48% of inhibition at 50 μM and their binding pattern exhibited interactions via hydrogen bonds with the key amino acid residues present on the RBD. Conclusion:: Compound B-8 can be used as a scaffold to develop new and more efficient antiviral drugs. conclusion: Compound B-8 can be used as a scaffold to develop new and more efficient antiviral drugs. other: None

Antiviral Activity of Acetylsalicylic Acid against Bunyamwera Virus in Cell Culture

Inhibition of Orbivirus Replication by Aurintricarboxylic Acid

Design, Synthesis and Anti-HIV-1 Evaluation of Novel Arylazolylthioacetanilides As Potent NNRTIS

Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways

In silico analysis of balsaminol as anti-viral agents targeting SARS-CoV-2 main protease, spike receptor binding domain and papain-like protease receptors

Potent Inhibition of Zika Virus Replication by Aurintricarboxylic Acid

Broad Antiviral Activity of Ginkgolic Acid against Chikungunya, Mayaro, Una, and Zika Viruses

Aminosugar derivatives as potential anti-human immunodeficiency virus agents

Preparation, Structure Elucidation, and Antiviral and Cytotoxic Activities of Acylation Derivatives of Cytochalasin B

In Vitro Evaluation of Anti-Rotaviral Activity and Intestinal Toxicity of a Phytotherapeutic Prototype of Achyrocline bogotensis (Kunth) DC

Synthesis and Antiviral Activity of a Series of Novel Quinoline Derivatives As Anti-Rsv or Anti-Iav Agents

Synthesis, Characterization and in vitro Evaluation of 4-(2-Aminoethyl)benzenesulfonamide Schiff Bases against Arboviruses

Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses

Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors

Novel Α,β-Unsaturated Amide Derivatives Bearing Α-Amino Phosphonate Moiety As Potential Antiviral Agents

Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs

Preliminary evidence that Bunyamwera virus causes severe disease characterized by systemic vascular and multiorgan necrosis in an immunocompromised mouse model

Antiviral activity of arbidol hydrochloride against herpes simplex virus I in vitro and in vivo

Berbamine inhibits the infection of SARS-CoV-2 and flaviviruses by compromising TPRMLs-mediated endolysosomal trafficking of viral receptors

Synthesis of Novel 1,3,4-Oxadiazole-Derived α-Aminophosphonates/ α-Aminophosphonic Acids and Evaluation of Their In Vitro Antiviral Activity against the Avian Coronavirus Infectious Bronchitis Virus

Structure-based Virtual Screening from Natural Products as Inhibitors of SARS-CoV-2 Spike Protein and ACE2-h Receptor Binding and their Biological Evaluation In vitro